Exercise stress cardiomyopathy-a case report
Abstract
Background: Stress cardiomyopathy (Takotsubo syndrome) is a characteristically reversible cardiomyopathy with several potential triggers. The condition has been described in the context of stress echocardiography, particularly following the use of pharmacological agents such as dobutamine. The association between Takotsubo syndrome and exercise stress echocardiography is less commonly reported.
Case summary: Exercise stress echocardiography was utilized in the investigation of dyspnoea in a 62-year-old female referred to the outpatient cardiology clinic. Inducible regional wall motion abnormalities were identified at peak stress, with associated ECG changes. Subsequent multimodality investigation, including cardiac magnetic resonance imaging, confirmed the diagnosis of stress cardiomyopathy, with coronary angiography revealing only minor coronary artery disease. Serial imaging was crucial in demonstrating complete resolution of the initial abnormalities, supporting the diagnosis.
Discussion: Takotsubo syndrome during stress echocardiography is a rare occurrence, with relatively few cases having been described in the context of exercise stress testing. This case demonstrated echocardiographic findings that were similar to major ischaemia. A comprehensive multimodality approach was required to exclude significant coronary artery disease and confirm the diagnosis of exercise stress cardiomyopathy.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.